[Tokyo/Geneva – 12 December 2018]
First multi-actor partnership tests chemical compounds for antibacterial activity
GARDP, Eisai, and Takeda have signed an agreement for GARDP to access and screen components of Eisai and Takeda’s chemical libraries. Both libraries will be tested by the Institut Pasteur Korea in the hope of discovering novel compounds with antibacterial activity. This multi-partner agreement supports GARDP’s efforts to tackle serious bacterial infections by developing antibiotics while endeavouring to ensure their sustainable access.
[Tokyo/Geneva – 12 December 2018]
배포일: 2018년 12월 12일
GARDP-에자이-다케다제약, 다자간 글로벌 파트너십 맺고 화합물 항균력 테스트 착수
한국파스퇴르연구소(소장: 류왕식)는 글로벌 항생제 연구개발 비영리 국제단체 (Global Antibiotic Research & Development Partnership, 이하 GARDP)와 일본계 글로벌 제약사들이 진행하는 새로운 항생제 개발 연구에 참여한다. GARDP는 최근 일본 글로벌 제약사 에자이(Eisai Co., Ltd., 이하 에자이), 다케다제약(Takeda Pharmaceutical Company Limited, 이하 다케다제약)과 항생제 개발 연구를 위한 다자간 파트너십 협약을 맺고 두 제약사가 제공하는 화합물 라이브러리를 활용한 항생제 개발 연구를 착수하였으며, 한국파스퇴르연구소 연구팀은 자체 구축된 초고속 약효검색 시스템을 이용하여 화합물 라이브러리로부터 항균물질 도출 및 검증 연구를 수행한다.
Global Antibiotic Research and Development Partnership (グローバル抗菌薬研究開発パートナーシップ、本部：スイス・ジュネーブ、以下「GARDP」)、エーザイ株式会社 (本社：東京都文京区、以下「エーザイ」) および武田薬品工業株式会社 (本社：大阪市中央区、以下「武田薬品」) は、抗菌活性を有する新たな化合物を発見することを目指し、エーザイおよび武田薬品の化合物ライブラリーを用いたGARDPによるスクリーニング実施に関する契約を締結しました。今後、エーザイおよび武田薬品から提供された化合物の抗菌活性試験はInstitut Pasteur Korea (所在地：キョンギド・ソンナム市、以下「韓国パスツール研究所」) にて実施されます。複数のパートナーによる本契約は、新規抗菌薬の開発と持続可能なアクセスの担保により、深刻な細菌感染症に立ち向かうGARDPの取り組みを推し進めるものです。
[4 December 2018]
Researchers analyzing the sales of oral antibiotics for children in 70 high- and middle-income countries found that consumption varies widely from country to country with little correlation between countries’ wealth and the types of antibiotics. Of concern is the relatively low-level use of amoxicillin, an antibiotic to treat the most common childhood infections. In addition, the review found the sale of antibiotics which should only be used for specific indications, or ‘Watch’ antibiotics in a quarter of all countries accounted for 20% of total antibiotic consumption. This is of concern since there is a higher risk of bacteria developing resistance to ‘Watch’ antibiotics.
[Geneva – 7 November 2018]
Results of a phase II clinical trial evaluating the safety and efficacy of zoliflodacin in patients with uncomplicated gonorrhoea have been published in the New England Journal of Medicine today. The data show zoliflodacin, an oral antibiotic, was well-tolerated and achieved very high microbiological cure rates, at urogenital sites, in patients with uncomplicated gonorrhoea.
[Geneva – 1 November 2018]
Funding supports delivery of R&D strategy that focuses on treating Gram-negative infections
GARDP is pleased to receive a EUR 50 million investment from the German Federal Ministry of Education and Research (BMBF). This funding is already contributing to accelerating the discovery, development, and delivery of affordable new and improved antibiotics to treat Gram-negative infections affecting both adults and children.
[Genf- 1 November 2018]
Der Fokus der Förderung liegt auf der Forschung und Entwicklung für Therapien gegen Infektionen mit Gram-negativen Erregern
GARDP dankt dem Bundesministerium für Bildung und Forschung (BMBF) für die Unterstützung mit Fördermitteln in Höhe von 50 Millionen Euro. Die Gelder tragen bereits dazu bei, die Entdeckung, Entwicklung und Bereitstellung von kostengünstigen neuen Antibiotika voranzutreiben. Diese neuen Antibiotika sollen die Behandlung von Erwachsenen und Kindern verbessern, die an Gram-negativen Infektionen erkrankt sind.
[Basel, Geneva – 27 September 2018]
GARDP and Novartis are joining forces to accelerate the development and availability of generic antibiotic treatments for children in low- and middle-income countries. The strategic partnership responds to the call from the World Health Organization for affordable, improved, and adapted antibiotic formulations and regimens for this vulnerable population, for which treatment options are limited.
[Geneva – 31 August 2018]
Funding supports delivering scientific strategy and development of R&D projects
GARDP is pleased to announce £1 million investment from the Wellcome Trust. This funding will contribute to accelerating the global development and delivery of affordable antibiotic treatments for drug-resistant bacterial infections.
[Geneva – 10 July 2018]
Seamus O’Brien, formerly of Pfizer, joins not-for-profit antibiotic developer
GARDP is pleased to welcome Seamus O’Brien as its first R&D Director. Seamus’s appointment completes recruitment of senior R&D positions as GARDP builds up a skilled team of experts from the antimicrobial field.
[New Delhi/Geneva – 3 July 2018]
Study aims to guide development of new treatments and reverse global increase in deaths of newborns
Over 80 researchers from 11 countries are meeting in New Delhi today to kick off an observational study to understand sepsis in newborns and current antibiotic prescribing practices. The observational study, led by GARDP, is benefiting from US$2 million funding from Bill & Melinda Gates Foundation.
[Geneva – 22 May 2018]
GARDP is pleased to announce a £1m investment from the UK Government’s Department of Health and Social Care. This funding will contribute towards accelerating the development of a new treatment for drug-resistant gonorrhoea with a primary focus on enabling sustainable access in low- and middle-income countries.
[Geneva – 22 May 2018]
PLOS, in collaboration with GARDP, is delighted to announce the launch of the Antimicrobial Resistance (AMR) Channel during the World Health Assembly, Geneva. This new channel offers the AMR research community access to the latest research, as well as commentaries, blogs, news, and discussions that span science, research and development, policy, and public health in the fight against AMR.
[26 April 2018]
Funding will support studies on new treatments for neonatal sepsis and drug-resistant STIs in South Africa
GARDP is pleased to announce the strengthening of its collaborative efforts with the SAMRC. This funding will contribute to the global development and delivery of affordable new or improved antibiotic treatments for drug-resistant bacterial infections where there are currently no adequate treatments, beginning with neonatal sepsis and sexually transmitted infections (STIs).
[22 February 2018]
Manica Balasegaram, co-author of the ‘Unavailability of old antibiotics threatens effective treatment for common bacterial infections’, comments following publication in The Lancet Infectious Diseases.
[25 January 2018]
The Global Antibiotic Research and Development Partnership (GARDP) welcomes DRIVE-AB’s acknowledgement that a combination of ways to apply and attract financial investments in research and development (‘push and pull incentives’) are required to effectively stimulate antibiotic innovation. We support many of their recommendations.